Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15762727 | 0.87 | ALDH1A1 (0.48) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL25046753 | 0.86 | APP (0.41) | APPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL27290352 | 0.86 | ROCK2 (0.41) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL21152897 | 0.86 | APP (0.41) | APPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23193237 | 0.84 | ROCK2 (0.45) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL23347013 | 0.84 | ROCK2 (0.42) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL13746231 | 0.84 | ROCK2 (0.42) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL25448141 | 0.84 | ROCK2 (0.42) | ROCK2ADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL9917266 | 0.84 | RXFP1 (0.44) | ROCK2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3074673 | 0.84 | APP (0.45) | APPMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024036329-A2 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11807690-B2 | Hyperglycosylated binding polypeptides | GENZYME CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| WO-2023186822-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | HOSPITAL SANT JOAN DE DEU (ES) | 2023-10-05 | — | — | WO | disclosed |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| WO-2018053552-A2 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | CELGENE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-9777013-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9580511-B2 | Site-specific antibody-drug conjugation through glycoengineering | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160320372-A1 | CARBOXY X RHODAMINE ANALOGS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-11-03 | — | — | US | disclosed |
| US-20130089555-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160320372-A1 | CARBOXY X RHODAMINE ANALOGS | PRCP, CPA3, CPA4 | APP 1283/4885ROCK2 1828/4885ADRB2 3260/4885 |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | APP 2082/4885ROCK2 178/4885ADRB2 4157/4885 |
| US-20170360952-A1 | BIOMOLECULE CONJUGATES | DNPEP, NAPA, NCL | APP 3079/4885ROCK2 2919/4885ADRB2 4299/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | APP 3734/4885ROCK2 3768/4885ADRB2 197/4885 |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | APP 4764/4885ROCK2 2344/4885ADRB2 4691/4885 |
| US-20180155762-A1 | 5,5-DISUBSTITUTED LUCIFERINS AND THEIR USE IN LUCIFERASE-BASED ASSAYS | GLB1, LUC7L2, GUSB | APP 4041/4885ROCK2 4527/4885ADRB2 3249/4885 |
| US-11807690-B2 | Hyperglycosylated binding polypeptides | UGGT1, B4GALT1, GALNT1 | APP 3312/4885ROCK2 4572/4885ADRB2 4718/4885 |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | APP 4383/4885ROCK2 2073/4885ADRB2 4454/4885 |
| US-20130089555-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | APP 4479/4885ROCK2 2840/4885ADRB2 3884/4885 |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | APP 1193/4885ROCK2 3834/4885ADRB2 2394/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | APP 4631/4885ROCK2 2790/4885ADRB2 4321/4885 |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | ERBB2, EGFR, TP53 | APP 2097/4885ROCK2 925/4885ADRB2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.